These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27744205)

  • 21. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials.
    Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.
    AlMukdad S; Elewa H; Arafa S; Al-Badriyeh D
    Int J Cardiol; 2021 May; 331():27-34. PubMed ID: 33535078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.
    Jiang M; You JH
    Pharmacogenet Genomics; 2015 Dec; 25(12):609-17. PubMed ID: 26398625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of ticagrelor versus clopidogrel with different dosage in high-risk patients with acute coronary syndrome.
    Xin YG; Zhang HS; Li YZ; Guan QG; Guo L; Gao Y; Yu HJ; Zhang XG; Xu F; Zhang YL; Jia DL; Sun YX; Qi GX; Tian W
    Int J Cardiol; 2017 Feb; 228():275-279. PubMed ID: 27865197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bedside testing of CYP2C19 vs. conventional clopidogrel treatment to guide antiplatelet therapy in ST-segment elevation myocardial infarction patients.
    Al-Rubaish AM; Al-Muhanna FA; Alshehri AM; Al-Mansori MA; Alali RA; Khalil RM; Al-Faraidy KA; Cyrus C; Sulieman MM; Vatte C; Loza BL; Claassens DMF; Asselbergs FW; Al-Ali AK
    Int J Cardiol; 2021 Nov; 343():15-20. PubMed ID: 34506827
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tailored antiplatelet therapy to improve prognosis in patients exhibiting clopidogrel low-response prior to percutaneous coronary intervention for stable angina or non-ST elevation acute coronary syndrome.
    Paarup Dridi N; Johansson PI; Lønborg JT; Clemmensen P; Radu MD; Qayyum A; Pedersen F; Kollslid R; Helqvist S; Saunamäki K; Kelbæk H; Jørgensen E; Engstrøm T; Holmvang L
    Platelets; 2015; 26(6):521-9. PubMed ID: 25166751
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genotype-Guided Antiplatelet Therapy Versus Standard Therapy for Patients with Coronary Artery Disease: An Updated Systematic Review and Meta-Analysis.
    Tang B; Wang X; Wang X; Liu L; Ma Z
    J Pharm Pharm Sci; 2022; 25():9-23. PubMed ID: 34995471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes: The PHARMCLO Trial.
    Notarangelo FM; Maglietta G; Bevilacqua P; Cereda M; Merlini PA; Villani GQ; Moruzzi P; Patrizi G; Malagoli Tagliazucchi G; Crocamo A; Guidorossi A; Pigazzani F; Nicosia E; Paoli G; Bianchessi M; Comelli MA; Caminiti C; Ardissino D
    J Am Coll Cardiol; 2018 May; 71(17):1869-1877. PubMed ID: 29540324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive cilostazol versus double-dose clopidogrel after drug-eluting stent implantation: the HOST-ASSURE randomized trial (Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis-Safety & Effectiveness of Drug-Eluting Stents & Anti-platelet Regimen).
    Park KW; Kang SH; Park JJ; Yang HM; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Chae IH; Kim HS
    JACC Cardiovasc Interv; 2013 Sep; 6(9):932-42. PubMed ID: 24050860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study.
    Collet JP; Hulot JS; Cuisset T; Rangé G; Cayla G; Van Belle E; Elhadad S; Rousseau H; Sabouret P; O'Connor SA; Abtan J; Kerneis M; Saint-Etienne C; Barthélémy O; Beygui F; Silvain J; Vicaut E; Montalescot G;
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1315-24. PubMed ID: 26265231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CYP2C19 genotyping combined with on-clopidogrel platelet reactivity in predicting major adverse cardiovascular events in Chinese patients with percutaneous coronary intervention.
    Tang XF; Han YL; Zhang JH; Wang J; Yao Y; He C; Xu B; Gao Z; Qiao SB; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Thromb Res; 2016 Nov; 147():108-114. PubMed ID: 27728892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Personalized antiplatelet therapy according to CYP2C19 genotype after percutaneous coronary intervention: a randomized control trial.
    Xie X; Ma YT; Yang YN; Li XM; Zheng YY; Ma X; Fu ZY; Ba Bayinsilema ; Li Y; Yu ZX; Chen Y; Chen BD; Liu F; Huang Y; Liu C; Baituola G
    Int J Cardiol; 2013 Oct; 168(4):3736-40. PubMed ID: 23850318
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thrombotic and bleeding events after coronary stenting according to clopidogrel and aspirin platelet reactivity: VerifyNow French Registry (VERIFRENCHY).
    Rangé G; Yayehd K; Belle L; Thuaire C; Richard P; Cazaux P; Barbou F; Köning R; Chassaing S; Teiger E; Berthier R; Decomis MP; Claudel JP; Delarche N; Brunel P; De Poli F; Dupouy P; Beygui F; Albert F; Collet JP; Montalescot G;
    Arch Cardiovasc Dis; 2014 Apr; 107(4):225-35. PubMed ID: 24794216
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
    Sibbing D; Koch W; Gebhard D; Schuster T; Braun S; Stegherr J; Morath T; Schömig A; von Beckerath N; Kastrati A
    Circulation; 2010 Feb; 121(4):512-8. PubMed ID: 20083681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Personalized antiplatelet therapy in patients with coronary artery disease undergoing percutaneous coronary intervention: A network meta-analysis of randomized clinical trials.
    Kheiri B; Abdalla A; Osman M; Barbarawi M; Zayed Y; Haykal T; Chahine A; Bachuwa G; Hassan M; Bhatt DL
    Catheter Cardiovasc Interv; 2019 Aug; 94(2):181-186. PubMed ID: 30628754
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of coexisting polymorphisms of CYP2C19 and P2Y12 on clopidogrel responsiveness and clinical outcome in patients with acute coronary syndromes undergoing stent-based coronary intervention.
    Tang XF; Zhang JH; Wang J; Han YL; Xu B; Qiao SB; Wu YJ; Chen J; Wu Y; Chen JL; Gao RL; Yang YJ; Yuan JQ
    Chin Med J (Engl); 2013 Mar; 126(6):1069-75. PubMed ID: 23506580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sex-Specific Differences in Clinical Outcomes After Percutaneous Coronary Intervention: Insights from the TAILOR-PCI Trial.
    Madan M; Abbott JD; Lennon R; So DYF; MacDougall AM; McLaughlin MA; Murthy V; Saw J; Rihal C; Farkouh ME; Pereira NL; Goodman SG;
    J Am Heart Assoc; 2022 Jun; 11(12):e024709. PubMed ID: 35699175
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of Ticagrelor Versus Clopidogrel Treatment in Patients With ST-elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
    Tang X; Li R; Jing Q; Wang Q; Liu P; Zhang P; Liu Y
    J Cardiovasc Pharmacol; 2016 Aug; 68(2):115-20. PubMed ID: 27010809
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Decreased platelet responsiveness to clopidogrel correlates with CYP2C19 and PON1 polymorphisms in atherosclerotic patients.
    Marchini JF; Pinto MR; Novaes GC; Badran AV; Pavão RB; Figueiredo GL; Lago IM; Lima-Filho MO; Lemos DC; Tonani M; Antloga CM; Oliveira L; Lorenzi JC; Marin-Neto JA
    Braz J Med Biol Res; 2017 Jan; 50(1):e5660. PubMed ID: 28076455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.